# Qiagen N.V. (QGEN) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $43.47, market value $9.0 billion.

## Valuation
- **P/E (trailing): 22.1×** (5-yr avg 44.4×, 3-yr avg 56.9×). Qiagen N.V. trades at 22.1× trailing earnings, well below its own five-year average of 44.4×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 16.7×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.04**. A PEG of 0.04 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 4.3×**. Each dollar of revenue is priced at 4.3×.
- **Price / book: 2.7×**. The shares trade at 2.7× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 13.9×**. Enterprise value is 13.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.9%** (5-yr avg 4.3%). Free cash flow equals 4.9% of the market value, in line with its five-year average of 4.3%.
- **Earnings yield: 4.5%**. The inverse of the P/E: 4.5% of the price is earned each year.

## Profitability
- **Gross margin: 62.2%**. Qiagen N.V. keeps 62.2% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 24.6%**. 24.6% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 20.3%**. 20.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 11.2%**. 11.2% on shareholders' equity is solid.
- **Return on invested capital: 10.0%**. Return on all capital, debt included, is 10.0%.
- **Return on assets: 6.5%**. Each dollar of assets produces 6.5% of profit.

## Growth
- **Revenue growth (1 yr): 5.7%** (3-yr -0.8%/yr, 5-yr 2.2%/yr). Revenue grew 5.7% over the last year, against 2.2% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 424.3%** (3-yr 1.8%/yr, 5-yr 4.9%/yr). Earnings per share rose 424.3%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -8.2%/yr**. Free cash flow has compounded at -8.2% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.44**. Debt is 0.44 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.2×**. It would take 1.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 13.1×**. Operating profit covers interest 13.1× over, a safe margin.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.81%** ($0.36 per share, trailing). Qiagen N.V. yields 0.81%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 13%**. 13% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 2**. 2 straight years of increases.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover Qiagen N.V.; the consensus is buy, with an average price target of $46.07 (+6% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -6.8%** (YTD -2.5%, 3-mo 19.6%). The shares are down 6.8% over twelve months including dividends.
- **From 52-week high: -24.8%** (33.6% above the low). Trading 25% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 0.34** (volatility 34%). Beta of 0.34 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=QGEN · Page: https://foliofundamentals.com/stocks/qgen

Not investment advice.